Media headlines about TG Therapeutics (NASDAQ:TGTX) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. TG Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.195266836978 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
TG Therapeutics (NASDAQ:TGTX) opened at $16.20 on Friday. The stock has a market capitalization of $1,243.29, a P/E ratio of -8.48 and a beta of 1.40. TG Therapeutics has a twelve month low of $7.25 and a twelve month high of $17.35.
TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 137.47% and a negative net margin of 77,945.40%. equities analysts predict that TG Therapeutics will post -1.68 EPS for the current fiscal year.
A number of analysts have commented on TGTX shares. B. Riley started coverage on TG Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $21.50 price objective for the company. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of TG Therapeutics in a report on Monday, January 8th. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Finally, BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $24.60.
In other news, CFO Sean A. Power sold 32,006 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at $4,398,444. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 16.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/03/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-tg-therapeutics-tgtx-stock-price.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.